Enablex
Indicated for bladder control, formulated to reduce urgency and target muscle contractions to support normal bladder function in patients.
Strengths: 7.5mg
Where to Check Availability
Medicine details
- Conditions
- Alternative names
Dartel
- Therapeutic class
Antimuscarinic
- Pharmacological class
Muscarinic Receptor Antagonist
- Contraindications
urinary retention; gastric retention; uncontrolled narrow-angle glaucoma
- Precautions and warnings
may cause blurred vision; use caution in patients with hepatic impairment
- Minor side effects
dry mouth; constipation
- Moderate side effects
dyspepsia; abdominal pain; urinary tract infection
- Serious side effects
urinary retention — requires immediate medical attention
- Dosage forms
Prolonged-release tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
Novartis
- Onset Time
1–2 weeks
- Duration
24 hours
- Storage instructions
Store below 25°C.
- Drug interactions
strong CYP3A4 inhibitors
- Age restrictions
Not for use in children.
- Pregnancy and breastfeeding
Pregnancy: No adequate data available. Breastfeeding: Use with caution.
Patient summary
Indicated for bladder control, formulated to reduce urgency and target muscle contractions to support normal bladder function in patients.
Mechanism of action
Darifenacin is a selective M3 muscarinic receptor antagonist. It specifically suppresses bladder muscle contractions by blocking muscarinic receptors, which helps alleviate the frequency, urgency, and incontinence associated with overactive bladder.
Enablex
Indicated for bladder control, formulated to reduce urgency and target muscle contractions to support normal bladder function in patients.
Editorial Notes
- Active ingredient(s): Darifenacin
- Listed indication(s): Overactive Bladder
Available option
- 60 tablets - 7.5 mg1531-7-5-mg-17836